InnoCare Pharma Limited
諾誠健華醫藥有限公司
（於開曼群島註冊成 立 的 有 限 公 司 ）
股份代號： 99 69
2022
年度報告
2022
2
8
9
14
17
21
61
68
93
115
122
123
124
125
127
129
213
AD
ALL
AML
AQP4 IgG 4
ASH
B B B T
B
Biogen Biogen Inc. BIIB
BTD
BTK BTK
CD20 B CD20 MS4A1 B
CDC
CDE NMPA
2 ┃
CLL
CNSL
9969
DLBCL B
DLT
EULAR
FGFR
FL
GMP
┃ 3
IBD
ICP-105
ICP-192
ICP-022
iDMC
IL-2 –2
IL-5 –5
IL-12 –12
IL-23 –23
IND
IRC
ITK T
ITP
iwNHL
JAK
4 ┃
MCD B (DLBCL) MYD88L265P
CD79B MCD
MCL B
MS
MZL
NDA
MMOSD
NMPA
NRDL
NTRK
FGFR (FGFR)
TRK
PD
┃ 5
PK
R/R r/r
R-CHOP
RICE
264,648.217
SC
0.000002
SHP2 RAS
SLE
SLL
SRI SLE
6 ┃
T T
T B NK
TDCC T
TRK
TYK2 2
UC
U.S.
FDA
Vivo Vivo Opportunity Fund, L.P Vivo Capital VIII, LLC
WM
┃ 7
183
17
1712-1716
1
8 8
248
40
Ogier Global (Cayman) Limited
89 Nexus Way
Camana Bay
Grand Cayman
KY1-9009
Cayman Islands
Ogier Global (Cayman) Limited 979
89 Nexus Way 27
Camana Bay
Grand Cayman
KY1-9009
Cayman Islands 9969
www.Innocarepharma.com
8 ┃
13 2
30
B T
B T
MS II 12
BTK II
12 Gd +T1
80 QD 92.1%(p=0.0006)
SLE IIa
SLE SRI –4
EULAR
CDE SLE
IIb
ITP II
PoC 50x10 L 9
7 36.4% 33 12 50
40% 15 6
ICP-332
ICP-332 2 TYK2 T
I I PK/PD
JAK-2 AE AD II
┃ 9
ICP-488
ICP-488 TYK2 TYK2 JH2 IL-23 IL12 I
IFN ICP-488
I
SAD MAD
ICP-248 ICP-490 ICP-B02
Tafasitamab
NHL MM
B DLBCL
NHL
BTK 565.9
214.7 164%
CSCO
NMPA MZL
NDA
CLL/SLL III
MCL II
NDA
–1 PD-1
EHA
10 ┃
NHL DLBCL
MCD B DLBCL III
R-CHOP R-CHOP
R-CHOP MCD DLBCL
ASCO 14 CRR 75%
66.67%
ICP-B04 Tafasitamab CD19 Minjuvi
Tafasitamab DLBCL
ASCT DLBCL Tafasitamab
CSCO ASCT DLBCL
Tafasitamab NMPA
ASCT B
DLBCL Tafasitamab DLBCL
Tafasitamab DLBCL
ICP-B02 (CM355)
ICP-B02 CD20xCD3 I
ICP-B02 B ICP-B02
SC IND CDE
MM
ICP-490
ICP-490
IND CDE I
┃ 11
ICP-248
ICP-248 B 2 BCL-2 BCL-2
ICP-248 IND CDE
I
ICP-192 ICP-723
ICP-192 (Gunagratinib)
ASCO-GI Gunagratinib CCA
IIa ICP-192 Gunagratinib FGFR2
CCA FGFR (52.9%)
CCA ICP-192 I/II
ICP-723 (Zurletrectinib)
I 20 DLT II RP2D 8
NTRK 75% ORR 12 9
PR RP2D 77.8% ORR 9 7 PR 12 IND
CDE CDE
ICP-189 ICP-B05 ICP-033
ICP-189
ICP-189 SHP2
Ia ICP-189
40 DLT PK
ICP-189 20 1 PR
12 ┃
ICP-B05 (CM369)
ICP-B05 C-C 8 CCR8
IND
I ICP-B05
┃ 13
8,697,927 5,928,716 3,969,640 3,969,640 1,876,618
10,321,158 7,397,531 4,537,710 2,615,693 2,201,159
2,676,831 1,738,612 1,738,612 5,563,439 3,039,533
625,404 1,043,033 1,364 1,247 1,617
(143,397) (65,667) – – –
198,199 217,938 271,304 104,449 31,395
(438,611) (298,463) (68,208) (3,458) (558)
(639,139) (721,584) (402,771) (213,123) (149,726)
(181,556) (139,815) (89,371) (63,623) (17,523)
(291,167) (1,271) (1,489) (2) (710)
(17,045) (2,642) (1,139) (1,916) (3,441)
- – – (69,181) (1,814,018) (387,804)
3,396 (51,014) (32,374) (159,907) (27,269)
(100) (32) – – –
(9,711) (604) – – (4)
– (46,558) – – –
(893,727) (66,679) (391,865) (2,150,351) (554,023)
0.60 0.05 0.40 9.32 2.83
14 ┃
625,404 1,043,033
198,199 217,938
(438,611) (298,463)
(639,139) (721,584)
(181,556) (139,815)
(291,167) (1,271)
(893,727) (66,679)
(473,691) 2,630
214.7 163.6%
565.9
625.4 1,043.0 417.6
776.0
217.9
198.2 (i) 57.1
(ii) 0.07 8.4
8.5 (iii) 16.3 29.9
46.2 (iv) 135.1 1.8
136.9
1,161.1 1,550.5
(i)
57.1 290.6
(ii) 304.5 115.4 419.9
273.0 2.5 (iii)
298.5 140.1 438.6
┃ 15
66.7
893.7
2.6
473.7
(893,727) (66,679)
290,559 (57,135)
129,477 126,444
(473,691) 2,630
16 ┃
12
BTKi
566 163.6%
300 1,500
CSCO CSCO
┃ 17
Tafasitamab CD19 Minjuvi
ASCT DLBCL Tafasitamab
FDA B DLBCL Tafasitamab
BLA 2022 CSCO
DLBCL Tafasitamab
13 30
ASCO DLBCL-MCD
DLBCL-MCD 75% CR III
MS II 12
Gd+T1 80 QD
92.1 II RMS
BTKi SLE IIa
SLE BTK
T ICP-332 TKY2 JH1 I ICP-488 TKY2 JH2
625
29
91
18 ┃
2.0
1.0
2.0
ICP-248 (BCL-2) ICP-490 (E3
Ligase) ICP-B02 (CD3xCD20) Tafasitamab (ICP-B04) (CD19)
DLBCL
B T
NCE B T
ICP-192 ICP-723
ICP-189 (SHP2) ICP-B05 (CCR8) ICP-033 (VEGFR,
DDR1)
┃ 19
20 ┃
Tafasitamab
163.6% DLBCL CD19 Tafasitamab
BLA
13
PoC MS ITP
1L DLBCL-MCD 1L CLL/SLL 1L MCL
MZL WM MCL ICP-192
SLE PoC MS
PoC 12
ITP II PoC BTKi
TYK2 ICP-332 ICP-488
CD3xCD20 BCL-2 E3 Ligase CCR8 SHP2
┃ 21
CMC
300
90
22 ┃
BTK
CLL/SLL MCL
625.4 565.9
163.6% 250
300 1,500 6,000
DOT
BTK
CSCO CLL/SLL MCL
BTK DLBCL pCNSL
┃ 23
IND Enabling Filed Market
PHIa PHIb PH2* PH2** PH3
CHN
r/r CLL/SLL 2020 12 25
CHN,SG
r/r MCL 2020 12 25
r/r MZL 2022 8 NDA NMPA
r/r WM 2022 NDA NMPA 2022
BTK 1L: CLL/SLL
ICP-022/
Orelabrutinib
1L: MCL
1L: MCD DLBCL
r/r MCL
HK
Tafa + LEN, r/r DLBCL
ICP-B04/
CD19
Tafasitamab
Tafa + LEN + Orela
NHL
ICP-B02 CD3 x CD20 2022 12
ICP-248 BCL-2
2023 3
NHL/ALL
ICP-490 E3 Ligase MM/DLBCL 2022 7
2023 3
ICP-B05 CCR8 Hemato-oncology
NDA
IND Enabling Filed Market
PHIa PHIb PH2* PH2** PH3
II PoC
ICP-022/
BTK
Orelabrutinib
ICP-332 TYK2 – JH1
ICP-488 TYK2 – JH2
ICP-192/ pan-FGFR
Gunagratinib
2023 2
ICP-723/ pan-TRK NTRK
Zurletrectinib
ICP-033 VEGFR, DDR1
ICP-189 SHP2 IND FDA
ICP-B05 CCR8
NDA
24 ┃
B T
B T
AD II
Psoriasis I
IBD
T LN
ICP-332 (TYK2i-JH1) CD
ICP-488 (TYK2i-JH2) UC
SLE
IIa IIb
B I IPoC
MS
II PoC
ITP
(BTKi)
NMOSD II
MS: CSU
NMOSD:
ITP:
CSU:
SLE:
AD:
IBD:
LN:
CD:
UC:
CNS B
SLE IIa
SLE BTK IIb
MS II PoC ITP NMOSD II
CSU
T
TYK2 ICP-332 ICP-488 T AD SLE
IBD LN CD UC
B ICP-332 ICP-488 T
┃ 25
B
BTK TEC B BCR
B BTK
BTK
MS
MS II II
RMS
OLE RMS 1:1:1:1
4 50 QD 50 BID 80 QD OLE
24
GdE T1 MRI 12
GdE T1 MRI
136 12 Gd+T1
50 QD 71.1% (p=0.0238) 50 BID 80.8%(p=0.0032)
80 QD 92.1%(p=0.0006)
12 Gd+T1
71.1%,
P=0.0238 80.8%,
P=0.0032 92.1%,
P=0.0006
Placebo Orela 50mg QD Orela 50mg BID Orela 80mg QD
N=34 N=33 N=35 N=34
1CI
QD= BID= p Pearson
26 ┃
24
RMS II
T1
(1)
Placebo-controlled(N = 136), 24Wk + ext Cumulative Gd+lesionsat Wk12 92.1% 80mg QD InnoCare
BTK
Tolebrutinib Placebo-controlled for 4Wk, with Dose-response for Gd+ (2)
85% 60mg QD Sano
BTK 12Wk cross-over (N=130), 16Wk + ext lesions at Wk 12
75mg qd
Placebo-controlled + open label DMF (N = Cumulative Gd+ lesions at Wk12, Merck
70%(3) (56% at
BTK 267),24Wk + ext 16, 20, and 24 KGaA
75mg bid)
Placebo-controlled + Inf-b1a reference Cumulative Gd+ lesions at (4)
89% 600mg q6mo Roche
CD20 arm (N=218), 24Wk + ext Wk 12, 16, 20, and 24
Placebo-controlled (N=231), 24Wk + Cumulative Gd+ lesions at 65% (5)(6)
60mg q12w Novartis
CD20 ext Wk 12 91%(7)
Placebo-controlled, adaptive, doseranging Dose-response for CUAL at
72%(8) 2mg qd Novartis
S1PR (N = 297), 6m + ext 3 mo
Cumulative Gd+ lesions at Wk12, (9)
Placebo-controlled(N = 257),24Wk + ext 69% 240mg tid Biogen
16, 20, and 24
61%(10)
Cumulative Gd+ lesions
Placebo-controlled (N = 281), 6m + ext 88% at 5mg qd Novartis
S1PR monthly for 6 months
mo. 6
(11)
Placebo-controlled (N = 179), 36Wk + ext # of CUAL per MRI scan 61% 14mg qd Sano
1 www.clinicaltrials.gov; (2)Sanofi’s R&D held on April 23, 2020;(3) MontalbanX, et al. N Engl J Med 2019; 380:2406-
2417;(4) KapposL, et al. Lancet 2011;378:1779-87 (5) Bar-Or A. et al, Neurology 2018;90:e1805-e1814; (6)Endpoint
with full data (0-12 Wks) (7) Post hoc data (4-12 wks);(8) Selmaj K, et al Lancet Neurol 2013;12:756-767;(9) Kappos
L, et al. Lancet 2008;372(9648):1463-72;(10) Kappos L, et al. N Engl J Med 2006; 355:1124-40;(11) O’Connor P, et al.
Neurology 2006;66(6)
MS MS
┃ 27
CNS PK BBB MS
PK BTK
evobrutinib tolebrutinib evobrutinib tolebrutinib
CNS
(CNS)
T
B
plasmacyte
T
T
AQP4
BTK+
B
MoG B
T
T
B
CSF Conc. ~2h
BTK (mg)
(ng/mL) (ng/mL)
Orelabrutinib InnoCare 150 QD 990 31.3
Evobrutinib Merck KGaA 75 BID 115 3.212
Tolebrutinib Sano 120 QD 13.4 1.871
1 doi: 10.1016/j.msard.2021.103000
2 Multiple Sclerosis and Related Disorders 51 (2021) 103001 Topic: Advances in therapy in MS; doi: 10.1016/
j.msard.2021.103001
28 ┃
EAE MS
MOG EAE EAE
EAE MS
MS DMT FDA Biolato M, Bianco A,
Lucchini M, Gasbarrini A, Mirabella M, Grieco A. The Disease-Modifying Therapies of Relapsing-Remitting
Multiple Sclerosis and Liver Injury: A Narrative Review. CNS Drugs . 2021 Aug;35(8):861-880
26 MS 26 24
22
HBV
DMT Biolato M, Bianco A, Lucchini M, Gasbarrini A, Mirabella M,
Grieco A. The Disease-Modifying Therapies of Relapsing-Remitting Multiple Sclerosis and Liver Injury: A
Narrative Review. CNS Drugs. 2021 Aug;35(8):861-880
ALT
┃ 29
ALT
β 1 3 6
1 3 6 9 12 C
6 2 C
6
B C
3
48
A
ALT
FDA
II MS IB ICF FDA
iDMC iHAC FDA
FDA
MS
MS
125
8.125
30 ┃
MS
90
B
MS II MS OLE
MS BTK
SLE
BTK BCR B
SLE
SLE II
EULAR
SLE 1:1:1:1 12
50 80 100
II
50 80 100 12
SRI-4 35.7% 50.0% 61.5% 64.3%
G C3 C4
┃ 31
IIa SLE
IIb SLE
SLE SLE
1:1:1 25 50 48
SRI-4 SRI-6 C3 C4 dsNDA
12 SRI-4
28.6%
100%
25.8%
90%
80% 14.3%
70% 61.5% 64.3%
60% 50.0%
50%
35.7%
40%
30%
50 80 100
20%
(N=14) (N=14) (N=13) (N=14)
10%
0%
(n=55)
50 80 100
SLE BTK evobrutinib
fenebrutinib Ringheim, G. E., Wampole, M., & Oberoi, K. (2021)
Frontiers in Immunology, 12, 662223 SLE BTK
SLE
ITP
ITP
ITP
T
BTK B ITP B
BTK ITP
ITP
32 ┃
ITP II II
ITP III
50×10 /L 9
2 7
22 GC IVIG
50 75.0% 8 6 36.4%
33 12 40% 15 6 50
II ITP
NMOSD
NMOSD
45-65 0.445/100,000 4.71:1
NMOSD B 4 AQP4 IgG 80%
AQP4 IgG BTK B B
BTK BTK
BTK NMOSD
IIT II IIT
┃ 33
T –TYK2
ICP-332
ICP-332 TYK2 TYK2 JAK
IL-12/IL-23 IFN
T 17 TH17 TH1 B
AD
ICP-332 TYK2 400 JAK2 JAK
TYK2 ICP-332
IBD
Pharma Intelligence 12
0.96-22.6% 1.2-17.1% 100
ICP-332
CDE ICP-332 I
I I PK/PD JAK-2
AE AD II
I 14
ICP-332 5 320 40 160 QD PK PD
8 ICP-332 6 2 80
ICP-322
ICP-332 5 320 PK Cmax AUClast
14
320 160 QD ICP-332
34 ┃
ICP-488
ICP-488 TYK2 JH2 JH2 TYK2 JH2
TYK2 ICP-488 TYK2 TYK2 JH2
IL-23 IL-12 I IFN ICP-488
SLE LN IBD ICP-332 ICP-488 TYK2
I 1
36 SAD MAD
ICP-488
ICP-248 ICP-490 ICP-B02
Tafasitamab
NHL MM
DLBCL
NM NHL (i)
(ii) FDA EMA CD19 Tafasitamab
DLBCL (iii) CD20xCD3 BCL-2 E3 Ligase (iv)
DLBCL
Tafasitamab BCL-2 E3 Ligase
DLBCL 1L DLBCL
MCD Tafasitamab DLBCL
ICP-490
ICP-B05
/CM369
ICP-B02
ICP-248
ICP-490 Orelabrutinib Tafasitamab ICP-248
PTCL/
MM Others CLL/SLL MCL MZL WM FL CNSL DLBCL AML ALL CML Others
CTCL
┃ 35
NHL
850
CLL/SLL MCL
CDE 5
MCL
AE 3
1L CLL/SLL
III CLL/SLL
IRC PFS
51
CLL/SLL
II CLL/SLL 150
80 CLL/SLL 47
56.2% ORR 93.8% CR 30%
1.84 DOR PFS
48 DOR PFS 56.2% 52.7%
CLL/SLL BTK CR
AE
CLL/SLL
Gazyva FCR
BTKi
7.16 11.07 3 PR/PR-L SD
ORR 75% DCR 100% BTKi CLL/CLL
1L MCL
III
R-CHOP R-CHOP IRC
iwNHL PFS
22
36 ┃
MCL
II MCL
DOR PFS OS
106 39.43
106 83%
87.8% CT 36.8%
MCL TRAE
3
MCL II FDA
BTD MCL
WM
WM B M IgM
BTK WM MYD88L265P
BTK BTK
WM IRC
MRR MRR ORR DOMR PFS OS
24.90 MRR 80.9% ORR 91.5% 12 DOMR
84.9% 12 PFS 81.2% PFS AE
3 3
(Lancet eClinicalmedicine)
MZL
II 150 MZL
111 90
MZL 90 MZL 53 PR 43 CR 10 IRC
ORR 58.9% 95% CI 48.0 69.2 DOR
┃ 37
34.3 95% CI NA NA PFS OS IRC 12
PFS OS 82.8% 91% ibrutinib MZL
ORR CR PFS OS
CDE CDE
MZL BTK
NHL DLBCL
1L DLBCL-MCD
DLBCL NHL 100
MCD 1L DLBCL III
R-CHOP R-CHOP MCD DLBCL IRC
PFS 45
40% DLBCL
R-CHOP+X MCD
B NF-KB BTK
T ITK CD20 NK
ADCC
R-CHOP MCD DLBCL
ASCO R-CHOP MCD DLBCL
14 MCD DLBCL 150
8 R-CHOP R-EPOCH 6 RICE R-CHOP R2
CRR 75% 66.67%
MCD DLBCL
MCD DLBCL
Tafasitamab (CD19) ICP-B02 (CD3xCD20) ICP-490 E3
DLBCL
38 ┃
pCNSL
pCNSL
pCNSL ND pCNSL CNSL
pCNSL ORR CR 88.9% 100% 53.9%
61.8% ND pCNSL
PFS mPFS 6 PFS 63.6% 100%
60% CNSL ORR 60% 86.7%
mPFS 9.8 3 mPFS
BCR MYD88 MOA
BBB 150 21.6 BBB
58.6%
pCNSL
BTK CD20
BTK B BCR CD20
CDC ADCC/ADCP
BTK 2 IL-2 -ITK NK ADCC
(Mol Ther Oncolytics 21: 158-170 2021
BTK BTK B
ADCC
Mol Ther Oncolytics 21:158-170 2021 Gazyva
ADCC ADCP CD20
CD19 Tafasitamab
┃ 39
BTKi + Gazyva (Obinutuzumab)
(Reporter assays: TMD8 as target cell)
Jurkat-NFAT-Luc2-CD16A-V158 Jurkat-NFAT-Luc2-CD32a-R167
2000 Gazyva 1500 Gazyva
Gazyva + Orelabrutinib (5M) Gazyva + Orelabrutinib (5M)
Luminescence (RLU)
Luminescence (RLU)
Gazyva + Ibrutinib (5M) Gazyva + Ibrutinib (5M)
ADCC
ADCP
1500
1000
1000
500
500
0 0
-2 -1 0 1 2 3 4 5 0 1 2 3 4 5
Log [Test Articles] (ng/mL) Log [Test Articles] (ng/mL)
CD20 Gazyva(obinutuzumab) ADCC ADCP
BTK
CD20/CD19 B
CD20 Gazyva B
Tafasitamab NHL II
ICP-B04 (Tafasitamab)
CSCO Tafasitamab
CSCO ASCT DLBCL
DLBCL CHOP
Tafasitamab
Tafasitamab
Tafasitamab Tafasitamab
NMPA
2 CR
Tafasitamab
18 Tafasitamab DLBCL
40 ┃
Tafasitamab DLBCL II
II Tafasitamab
DLBCL ORR IRC DCR DoR PFS
TTP TTR OS 24
Tafasitamab B DLBCL
NHL 40% Frost & Sullivan DLBCL 59
119 NHL/DLBCL Tafasitamab
Incyte Tafasitamab Fc CD19
Tafasitamab FDA
DLBCL DLBCL
ASCT II L-MIND 57.5% ORR(40% CR) 33.5
mOS 43.9 mDoR Tafasitamab
CD19 B-NHL B-NHL
RE-MIND2 R2 Tafasitamab
Incyte 35 Incyte
82.5
Tafasitamab
Incyte BTK
Tafasitamab Tafasitamab B
Tafasitamab ADCC
ADCP B CD19
Incyte Tafasitamab
┃ 41
ICP-B02 (CM355)
ICP-B02 CD20xCD3
TDCC ICP-B02
50%
ICP-B02 50%
I/II ICP-B02 NHL PK
I ICP-B02 DLT
5 3+3
DLT ICP-B02 B ICP-B02 SC IND
CDE
MM
ICP-490
ICP-490 CRBN E3 TPD
CRL4CRBN-E3 ICP-490 IKZF1 Ikaros IKZF3 Aiolos
ICP-490 CRBN E3
Aiolos Ikaros ICP-490
MM B DLBCL ICP-490
CRNB ICP-490 ADCC
CD38 daratumumab
ICP-490 DLBCL
ICP-490
MM IMiD MM NHL
IND CDE I
42 ┃
ICP-248
ICP-248 B 2 BCL-2 BCL-2
BCL-2
BCL-2
ICP-248
ICP-248 BCL-2
ICP-248 ALL
AML FL CLL DLBCL BCL-2
10% 20 ICP-248
ICP-248 IND CDE I
I ICP-248 B CLL/
SLL MCL ICP-248 ICP-248
CLL/SLL
ICP-192 ICP-723
ICP-189 ICP-B05 ICP-033
┃ 43
ICP-192 (Gunagratinib)
20
ORR 52.9% DCR 94.1%
ICP-723 (Zurletrectinib)
NTRK
8 ORR 75%
RTKi EGFRi VEGFi KRASi RAFi
MEKi CDK4/6i PD-1/PD-L 1 ICI
ICP-189 ICP-B05
SHP-2 CCR8
FGFR ICP-192 TRK ICP-723
SHP2 CCR8 ICP-189
ICP-B05 ICP-033
ICP-192 (Gunagratinib)
Gunagratinib
FGFR FGFR
7.1%
FGFR
44 ┃
Gunagratinib FGFR FGFR
Gunagratinib FGFR
Gunagratinib CCA IIa
ICP-192 18 CCA 17 5.57
ORR 52.9% 17 9 DCR 94.1% 17 16 mPFS 6.93
95% CI 5.42 TRAE
FGFR Gunagratinib CCA
FGR2 (52.9%)
Gunagratinib I/II
II II ORR
44.4% 9 4 DCR 88.9% 9 8
ICP-723 (Zurletrectinib)
ICP-723 TRK TRK
TRK NTRK TRK
TRK ICP-723
TRKA/B/C TRKA G595R G667C ICP-723
TRK ICP-723 ROS1 ROS1
TRK TRKA TRKB TRKC NTRK1
NTRK2 NTRK3 TRK NTRK NTRK
NTRK
C-Ros 1 (ROS1)
NSCLC ROS1 NSCLC
┃ 45
I/II ICP-723 NTRK/ROS1
PK ASCO
I/II I II I
II NTRK
ROS1 TRK ROS1
I 24 DLT II RP2D
8 NTRK 75%
ORR 12 9 PR 8 77.8% ORR 9 7 PR 6 ROS1
ORR 50% 4
PR DLT
12 IND CDE CDE EoP2
ICP-189
ICP-189 SHP2 ICP-189
SHP2 RAS-MAPK
PD-1 SHP2
ICP-189
ICP-189 EGFR KRAS MEK PD-1
Ia ICP-189
40 DLT 3
TRAE SAE ICP-189 20 1 PR
ICP-189 PK ICP-189 Ib
ICP-189 EGFR PD-1
ICP-189 IND FDA
46 ┃
ICP-B05 (CM369)
ICP-B05 C-C 8 CCR8
CCR8 TME
T Tregs CM369 Tregs CCR8 ADCC
Tregs TME CM369
T
ICP-B05 IND CDE
I ICP-B05
ICP-B05
ICP-033
ICP-033 1 DDR1 VEGFR
ICP-033 ICP-033
ICP-033 I
PROTAC XDC
50,000 GMP
NMPA BTK
┃ 47
30,000
CMC
70,381
29.19
48 ┃
MS BTK
90
% %
566,755 90.6 214,666 20.6
58,649 9.4 52,404 5.0
– – 775,963 74.4
625,404 100.0 1,043,033 100.0
1,043.0
625.4
352.1 164.0% 566.8
776.0
% %
471,170 97.8 191,008 19.5
10,837 2.2 10,395 1.1
– – 775,963 79.4
482,007 100.0 977,366 100.0
977.4 93.7%
482.0 77.1%
8
┃ 49
217.9
198.2 (i) 57.1
(ii) 0.07 8.4
8.5 (iii) 16.3 29.9
46.2 (iv) 135.1 1.8
136.9
721.6
639.1
% %
2,490 0.4 273,026 37.8
196,826 30.8 167,589 23.2
223,095 34.9 136,923 19.0
58,164 9.1 39,428 5.5
43,083 6.7 21,837 3.0
115,481 18.1 82,781 11.5
639,139 100.0 721,584 100.0
(i) 273.0 270.5 2.5
(ii) 167.6 29.2 196.8
(iii) 136.9 86.2 223.1
(iv) 39.4 18.8 58.2
(v) 21.8 21.3 43.1
(vi) 82.8 32.7
115.5
50 ┃
139.8
181.6 (i) 47.0
78.0 (ii) 3.6
11.3 (iii) 1.4 6.9 (iv)
9.2 15.8
% %
78,008 43.0 46,964 33.6
34,357 18.9 43,017 30.8
35,159 19.4 35,563 25.4
11,297 6.2 3,637 2.6
6,895 3.8 1,392 1.0
15,840 8.7 9,242 6.6
181,556 100.0 139,815 100.0
298.5
438.6 (i)
126.5 219.4 (ii) 100.7
143.1
% %
219,422 50.0 126,462 42.4
143,105 32.6 100,712 33.7
36,956 8.5 43,999 14.7
39,128 8.9 27,290 9.2
438,611 100.0 298,463 100.0
┃ 51
57.1
290.6
51.0
3.4
9.7
0.6
2.6
17.0
46.6
52 ┃
127,825 45,273
95,344 116,145
65,322 9,918
313,290 317,059
8,697,927 5,928,716
9,299,708 6,417,111
118,597 84,602
4,242 6,831
727,552 204,886
7,757 12,647
20,112 20,336
1,197,168 –
2,075,428 329,302
7,224,280 6,087,809
7,224.3
8,697.9 127.8
95.3 313.3
727.6 118.6 1,197.2
┃ 53
127,822 45,273
3 –
127,825 45,273
116.1
95.3
16.3 16.3
33,557 37,532
44,987 41,363
– 16,340
12,147 17,362
4,653 3,548
95,344 116,145
313.3
317.1 304.7
54 ┃
9.9
65.3
111,186 84,459
7,335 121
66 17
10 5
118,597 84,602
90
204.9
727.6 (i)
47.0 104.1 (ii)
41.4 57.0 (iii)
33.1
7.6 (iv) 23.0
51.4 (v)
459.5
104,050 46,956
57,014 41,406
32,580 37,360
7,628 33,070
51,391 23,024
– 20,000
459,517 –
15,372 3,070
727,552 204,886
┃ 55
20,112 20,336
459,517 –
1,197,168 –
35,439 47,442
287,761 37,693
– 1,200,564
1,999,997 1,306,035
1,306.0
2,000.0
136.3
286.0
430.1
653.2
136.0
284.1
34.2
41.3 SAP
21.4
11.7
56 ┃
51.0
28.0
4.5 19.5
1,197.2
204.9 727.6
84.6 118.6
5,928.7
8,697.9
8.95 250,324,000
0.000002 3,883 2,240.4
H.10
37,548,000
15% 322.59
210,508,000
14.45
┃ 57
264,648,217 0.000002
11.03
2,778.82
9,011.2
6,550.5
715
(i) 8.5
(ii) 6.6
300
100% 18.8% 17%
58 ┃
1,197.2
287.8 459.5
163.4
26 28 29
┃ 59
939
418 44.5%
150 16%
261 27.8%
110 11.7%
939 100%
60 ┃
Ph.D. 60
20
Merck Co
PPD BioDuro LLC (Sino-
American Pharmaceutical Association) 17 50
Nature Blood Proceedings of the National Academy of Sciences Journal of Biological
Chemistry Transgenic mice expressing APC resistance
Factor V cloning and expression of dog gonadotropin releasing hormone receptor DNA encoding
monkey gonadotropin releasing hormone receptor
(Purdue
University) (The Howard
Hughes Medical Institute)
Ph.D. 54
Shenzhou Tianchen Technology Inc
(Johns Hopkins University)
┃ 61
Ph.D. 55
(Princeton University)
(The National Science Fund for Distinguished Young Scholars)
(The Irving Sigal Young Investigator Award)
(The Raymond & Beverly
Sackler International Prize)
(The Gregori Aminoff Prize, Royal Swedish Academy
of Sciences)
(The National Innovation Award)
Structures of the Human Spliceosomes Before and After Release of the Ligated Exon
Structures of the Catalytically Activated Yeast Spliceosome Reveal the Mechanism of Branching
Recognition of the Amyloid Precursor Protein by Human -Secretase
62 ┃
Structural Basis of Notch Recognition by Human -Secretase
Structure of a Human Catalytic Step I Spliceosome
Structures of the Fully Assembled Saccharomyces Cerevisiae Spliceosome Before Activation
Structure of the Human PKD1/PKD2 Complex
Structures of the Human Pre-Catalytic Spliceosome and its Precursor Spliceosome
(Johns Hopkins University)
55
Blackstone (Shanghai) Equity Investment Management
Company Limited Vivo Capital LLC
01875
Sinovac Biotech Co , Ltd.
SVA Genetron Holdings Limited
GTH
2291
38 10
Oriza Cowin
688578
09926
02171
┃ 63
49
20
7
Ph.D. 55
Genentech Inc
Analytical BioSciences Limited
51
20
1875
Arther Andersen
CICPA
64 ┃
Ph.D. 77
1349 Zai Lab Limited
ZLAB 9688
1801
600557
┃ 65
Ph.D. 60
61
30 20
Merck & Co.
Bristol-
Myers Squibb GlaxoSmithKline
Hengrui Therapeutics Inc. (HTI) Princeton
(USMLE)
(FCP)
51
20
Bruker Daltonics China
66 ┃
Ph.D. 56
IND
23 17
Albert Einstein College of Medicine
Pfizer Inc
┃ 67
129 1
122 128
31
125
68 ┃
14
430.1
653.2
13
8.08
┃ 69
2,415.67 1,260.2
52.2%
50% 1,207,835 853,114 441,116 411,998
40% * 966,268 812,054 115,853 696,201
10% 241,567 63,666 16,350 47,316
2,415,670 1,728,834 573,319 1,155,515
*
(i) (ii)
70 ┃
Gaoling Fund L.P. YHG Investment L.P. Vivo Opportunity Fund, L.P.
210,508,000
16.33% 14.04% 14.45
421.02 3,041.44 210,508,000
14.45
15.72 3,041.84 3,041.44
3,041,440 1,704,498 1,336,942
2,919.07
140.25 2,778.82
545.7
┃ 71
1,494,220.6 – 1,494,220.6
116,146.6 – 116,146.6
273,851.4 – 273,851.4
60,952.3 – 60,952.3
833,644.7 – 833,644.7
2,778,815.6 – 2,778,815.6
72 ┃
183 17 1712-1716
622 5
┃ 73
13.91 27
571
74 ┃
EHS
EHS
┃ 75
1.0
2.0
B T
Multiple Sclerosis International Federation MSIF 280
MS Frost & Sullivan MS 230
317 BTK B MS
BTK MS
BBB MS
BTK II MS MS BTK
B
SLE IIa SLE BTK
ITP NMOSD II
T
ICP-332 ICP-488 T AD SLE LN
IBD B ICP-332 ICP-488 T
76 ┃
ICP-248 ICP-490 ICP-B02
Tafasitamab MM NHL
B
MZL WM CLL/SLL MCL MCD DLBCL
MCL
NHL
ICP-192 ICP-723
ICP-189 ICP-B05 ICP-033
IND
ICP-B02 ICP-B05 Tafasitamab
┃ 77
78 ┃
114(a)
118
117
61 67
13.51B(1)
┃ 79
3.13
XV (a) XV 7 8
(b) 352 (c)
(1)
103,222,916(2) 5.85%
119,839,593 (3)
6.79%
119,839,893 (4)
6.79%
8,311,111 0.55%
(1) 1,764,321,452
(2) (i) Sunland BioMed Ltd 82,326,827 (ii)
20,896,089
(3) (i) Sunny View Holdings Limited 99,360,375 (ii)
20,479,218
(4) XV
80 ┃
XV XV
7 8
352
XV 2 3
XV 336
(1)
TMF (Cayman) Ltd. 89,014,653(2) 5.04%
GIC Private Limited 97,614,645(3) 5.53%
Vivo Capital VIII, LLC 123,028,118(4) 6.97%
Hebert Pang Kee Chan 163,444,332(5) 9.30%
HHLR Advisors, Ltd. 208,671,222(6) 11.83%
(1) 1,764,321,452
(2) Golden Autumn Group Limited Strausberg Group Limited 47,900,278 41,114,375 Golden
Autumn Group Limited Strausberg Group Limited Lakeview Trust Summit Trust TMF
(Cayman) Ltd
Lakeview Trust Summit Trust TMF (Cayman) Ltd
47,900,278 41,114,375 890,014,653
(3) Highbury Investment Pte Ltd 42,559,355 Highbury Investment Pte Ltd
Loyal Valley Capital Advantage Fund II LP 45,487,484 LVC Lion Fund LP
Loyal Capital Advantage Fund II LP LVC Lion Fund LP 9,567,806
Highbury Investment Pte Ltd GIC (Ventures) Private
Limited GIC Special Investments Private Limited GIC Special Investments Private Limited GIC Private
Limited GIC (Ventures) Private Limited GIC Special Investments Private
Limited GIC Private Limited Highbury Investment Pte Ltd 97,614,645
┃ 81
(4) Vivo Capital LLC (i) Vivo Opportunity Co-Invest, L.P. (ii) Vivo Capital Fund IX, L.P. (iii) Vivo Opportunity Fund, L.P.
(iv) Vivo Capital Surplus Fund VIII, L.P. (v) Vivo Capital Fund VIII, L.P. Vivo
2,699,286 1,891,627 24,673,087 11,376,779 82,387,339 Vivo
Capital LLC Vivo Vivo 123,028,118
(5) Hebert Pang Kee Chan 163,444,332 (i) Success Growth Limited 55,500,000
(ii) King Bridge Investments Limited 106,807,145 (iii) 1,137,187
Success Growth Limited 55,500,000 Success Growth Limited King Bridge
Investments Limited Hebert Pang Kee Chan Hebert Pang Kee Chan Golden
Sage Investments Limited
(6) HHLR Advisors, Ltd. Hillhouse Capital Advisors, Ltd. HHLR Fund, L.P. Gaoling Fund, L.P. YHG
Investment, L.P. Hillhouse HHLR Fund L.P. 200,475,300
HHLR Advisors, Ltd. Hillhouse Hillhouse
208,671,222
XV 2 3
XV 336
8.10
82 ┃
37
14A.49 14A.71
┃ 83
939 721
8 9
1.
(i) (ii)
(iii)
84 ┃
2.
3.
┃ 85
274,586,514 183,888,050
22,200,000 68,498,464
15.56% 10.42%
1.26% 3.88%
222,308,157 84,894,476 Golden Autumn Group Limited
Strausberg Group Limited
Golden Autumn Group Limited Strausberg Group
Limited Lakeview Trust Summit Trust TMF (Cayman)Ltd.
(10%)
0.000002 0.178
52,278,357 2.96%
17.12
86 ┃
33
2022
12 31
2022 2022
(3) (1) (4)
1 1 12 31
3,333,333 0 3,333,333 0 0 0 0 2015 1.2253
3,333,333 0 3,333,333 0 0 0 0
11,900,000 0 0 0 0 0 11,900,000 2018
11,900,000 0 0 0 0 0 11,900,000
┃
87
88
2022
12 31
2022 2022
(3) (1) (4)
1 1 12 31
┃
4,655,712 0 441,205 990,000 0 0 3,224,507 2015 1.2253
3,000,000 0 525,000 0 0 0 2,475,000 2016 1.2941
14,682,000 2,700,000 3,414,000 1,734,750 0 0 12,233,250 2018 03/16/2022 1.091 2022/3/16- 0.178 9.93 1.1640
2026/3/15
04/28/2022 1.1806 0.178 10.66
(2)
09/16/2022 1.2234 2022/9/16- 0.178 11
2026/9/15
22,337,712 2,700,000 4,380,205 2,724,750 0 0 17,932,757
37,571,045 2,700,000 7,713,538 2,724,750 0 0 29,832,757
(1) 33 2.4
(2)
(3)
(4) 17.07(3)
17
17 17
10% 10%
128,916,524 7.3%
128,916,524 128,916,524
┃ 89
17 17
17.12
12.8% 34.6%
13.1% 41.6%
5%
90 ┃
0.5
C.2.1
(i)
(ii)
(iii)
┃ 91
13.17 13.22
92 ┃
C.2.1
90
┃ 93
(www.innocarepharam.com)
4
(www.innocarepharam.com)
(www.innocarepharam.com)
94 ┃
┃ 95
(1)
(2)
13/13 – 2/2 2/2 1/1
13/13 – – – 1/1
13/13 – – – 0/1
2/2 – – – –
13/13 – – – 1/1
13/13 – – – 0/1
11/11 – – – 0/1
13/13 5/5 2/2 2/2 0/1
13/13 5/5 2/2 – 0/1
13/13 5/5 – 2/2 0/1
(1)
(2)
96 ┃
3.10(1) (2) 3.10A
3.13
C.2.7
┃ 97
C.1.4
1
1.
98 ┃
(i)
(ii)
(iii)
114. (a)
118
┃ 99
3.10(2) 3.21
(i)
(ii)
(iii)
100 ┃
17
17.07A
4,500,001 5,000,000 1 –
9,000,001 9,500,000 – 1
10,500,001 11,000,000 – 1
15,500,001 16,000,000 1 –
17,000,001 17,500,000 – 1
28,000,001 28,500,000 1 –
30,500,001 31,000,000 1 –
36,500,001 37,000,000 – 1
4 4
8 9
┃ 101
16,108 12,873
7,424 4,941
343 253
70,247 72,670
– 33
94,122 90,770
(a)
(b)
(c)
102 ┃
18
┃ 103
(i) (ii)
A.2.1
3.29 15
104 ┃
(i)
(ii)
(iii) (iv)
(v)
┃ 105
(i) (ii)
(iii) (iv) (v)
(vi) (vii)
(viii)
(i)
(ii)
(iii) (iv)
(v) (vi)
106 ┃
(i) (ii)
12
┃ 107
(www.innocarepharam.com)
(www.innocarepharam.com)
108 ┃
5,683
2,000
500
8,183
38 77
┃ 109
(6) (3)
(4) (3) (2)
<=50 50-69 =>70
(2) (3) (1)
0-1 2-3 4-5 >=6
(2) (2) (3) (2)
0 1-2 3-4 >=5
(5) (1) (3) (0)
(i) (ii) (iii)
(iv)
939 501
438 43.4% 46.6%
110 ┃
66
21 21 21
119
┃ 111
www.innocarepharma.com
8 8
ir@innocarepharma.com
26 30
900
112 ┃
(i) (ii)
115 121
┃ 113
114 ┃
Ernst & Young
27/F, One Taikoo Place
979 King’s Road
Quarry Bay, Hong Kong
122 128
┃ 115
639,139,000
(1)
(2)
(3)
(4)
2.4
6 (5)
(6)
116 ┃
625,404,000 (1)
(2)
(3)
2.4
3 5 (4)
(5)
(6)
(7)
┃ 117
(1)
(2)
9
(1)
1,197,168,000
(2)
2.4 (3)
3 28 39
118 ┃
┃ 119
120 ┃
Shun Lung Wai, Ricky
┃ 121
5 625,404 1,043,033
(143,397) (65,667)
482,007 977,366
5 198,199 217,938
(438,611) (298,463)
(639,139) (721,584)
(181,556) (139,815)
(291,167) (1,271)
28 3,396 (51,014)
(100) (32)
(9,711) (604)
7 (17,045) (2,642)
(893,727) (20,121)
10 – (46,558)
(893,727) (66,679)
(886,593) (64,545)
(7,134) (2,134)
(893,727) (66,679)
12 0.60 0.05
122 ┃
(893,727) (66,679)
429,445 (89,453)
429,445 (89,453)
(464,282) (156,132)
(457,148) (153,998)
(7,134) (2,134)
(464,282) (156,132)
┃ 123
13 653,163 430,081
14 284,103 135,999
15 3,125 3,125
16 41,305 34,166
17 11,712 21,423
22 – 304,675
18 28,042 50,951
1,021,450 980,420
19 65,322 9,918
20 127,825 45,273
21 95,344 116,145
22 313,290 317,059
23 8,697,927 5,928,716
9,299,708 6,417,111
24 118,597 84,602
25 4,242 6,831
26 727,552 204,886
27 7,757 12,647
14 20,112 20,336
28 1,197,168 –
2,075,428 329,302
7,224,280 6,087,809
8,245,730 7,068,229
28 – 1,200,564
14 35,439 47,442
29 287,761 37,693
27 278,203 123,611
601,403 1,409,310
7,644,327 5,658,919
31 23 19
32 7,597,078 5,604,540
7,597,101 5,604,559
47,226 54,360
7,644,327 5,658,919
124 ┃
31 31 32(a) 33 32(b)
19 9,371,726 (19,292) 260,235 (6,036) (465,758) (3,536,335) 5,604,559 54,360 5,658,919
– – – – – (886,593) (886,593) (7,134) (893,727)
– – – – – 429,445 – 429,445 – 429,445
– – – – – 429,445 (886,593) (457,148) (7,134) (464,282)
A 4 2,919,066 – – – – – 2,919,070 – 2,919,070
– (149,902) – – – – – (149,902) – (149,902)
33 – – – 129,477 – – – 129,477 – 129,477
– 68,629 – (64,345) – – – 4,284 – 4,284
– (453,239) – – – – – (453,239) – (453,239)
23 11,756,280* (19,292)* 325,367* (6,036)* (36,313)* (4,422,928)* 7,597,101 47,226 7,644,327
┃ 125
31 31 32(a) 33 32(b)
16 6,743,236 (19,292) 234,183 (6,036) (376,305) (3,471,790) 3,104,012 56,494 3,160,506
– – – – – – (64,545) (64,545) (2,134) (66,679)
– – – – – (89,453) – (89,453) – (89,453)
– – – – – (89,453) (64,545) (153,998) (2,134) (156,132)
31 3 2,526,672 – – – – – 2,526,675 – 2,526,675
33 – – – 126,444 – – – 126,444 – 126,444
– 101,818 – (100,392) – – – 1,426 – 1,426
19 9,371,726* (19,292)* 260,235* (6,036)* (465,758)* (3,536,335)* 5,604,559 54,360 5,658,919
* 7,597,078,000 5,604,540,000
126 ┃
(893,727) (20,121)
100 32
7 17,045 2,642
290,559 (44,138)
5 (136,914) (135,135)
5 (8,486) (70)
17 9,711 604
28 (3,396) 51,014
5 (6,557) (6,733)
(73) –
6 35,353 10,438
6 21,533 17,752
11,517 5,521
– 2
6 129,477 126,444
(533,858) 8,252
(52,116) (8,040)
(82,653) (45,153)
(932) (1,349)
33,995 79,082
35,354 76,565
(8,748) 17,191
(608,958) 126,548
43,404 40,510
(565,554) 167,058
98,372 79,568
– (715,000)
315,000 2,611,467
(227,235) (169,770)
(11,724) (1,441)
74,971 –
(20,000) (868)
– 19
(131,368) –
(1,824,370) (3,533,940)
(1,726,354) (1,729,965)
┃ 127
4,160 784
A 2,919,070 –
(128,686) (15,207)
– 2,526,675
325,000 50,000
(3,263) (2,529)
(21,775) (14,916)
3,094,506 2,544,807
802,598 981,900
3,237,484 2,300,881
139,902 (45,297)
23 4,179,984 3,237,484
23 8,697,927 5,928,716
23 (4,515,379) (2,691,009)
(2,564) (223)
23 4,179,984 3,237,484
128 ┃
1.
Ogier
Global (Cayman)Limited, 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009 Cayman Islands
1 100% –
1 – 100%
InnoCare Pharma Inc. 10,000,000 – 100%
InnoCare Pharma Australia Pty Ltd. 10 – 100%
(a) 80,000,000 – 100%
10,000,000 – 100%
49,225,100 – 91.08%
4,000,000 – 100%
1,000,000,000 – 93%
(a) 30,000,000 – 100%
(a)
┃ 129
2.1
(a)
(b)
(c)
130 ┃
2.1
(i) (ii)
(iii) (i) (ii)
(iii)
2.2
3
16
37
1 9
16 41
(a) 3
3
37 21
3 37
21
┃ 131
2.2
(b) 16
2
(c) 37 37
(d) 1
9 16 41
9
132 ┃
2.3
10 3
28
16 2
17 1
17 1, 5
17 17 9
6
1 2, 4
1 2
1 1
2
8 1
12 1
1
2
3
4
5
5 17 4
39 9
6 17
┃ 133
2.3
10 28 10
28
10
28
16
16
1
12
12
134 ┃
2.3
1
2
1
2
8
12 12
12
7,852,000
7,877,000
┃ 135
2.4
20%
5
136 ┃
2.4
┃ 137
2.4
138 ┃
2.4
–
–
–
┃ 139
2.4
(a)
(i)
(ii)
(iii)
(b)
(i)
(ii)
(iii)
(iv)
(v)
(vi) (a)
(vii) (a)(i)
(viii)
140 ┃
2.4
5
5%
10% 33 /3%
1
10% 331/3%
162/3%
┃ 141
2.4
10
3 10
142 ┃
2.4
(a)
1 6
50
(b)
┃ 143
2.4
(c)
12
15
SPPI SPPI
144 ┃
2.4
┃ 145
2.4
(a) (b)
146 ┃
2.4
12 12
– 12
–
–
┃ 147
2.4
9
28
148 ┃
2.4
┃ 149
2.4
150 ┃
2.4
┃ 151
2.4
15
152 ┃
2.4
(a)
(a) (b)
┃ 153
2.4
(a)
15.85
154 ┃
2.4
(a)
(b)
┃ 155
2.4
(a)
(b)
(c)
156 ┃
2.4
33
┃ 157
2.4
158 ┃
2.4
┃ 159
3.
(i)
160 ┃
3.
(ii)
(iii)
┃ 161
3.
3,125,000
3,125,000 15
38
22 38
28
38
33
162 ┃
3.
1,511,700,000
1,177,329,000 10
┃ 163
4.
(a)
568,035 216,066
57,369 826,967
625,404 1,043,033
(b)
1,020,695 674,729
755 1,016
1,021,450 675,745
10%
A * 826,967
B 224,090 *
C 101,386 *
D 81,916 *
407,392 826,967
* 10%
164 ┃
5.
625,404 1,043,033
(a)
– 775,963
566,755 214,666
57,369 51,003
1,280 1,401
625,404 1,043,033
568,035 216,066
57,369 826,967
625,404 1,043,033
568,035 992,030
57,369 51,003
625,404 1,043,033
Biogen Inc.
MS BTK
90
┃ 165
5.
(a)
7,797 –
(b)
60
30 90
90
17,783 7,797
– 17,783
17,783 25,580
166 ┃
5.
(b)
1
46,159 16,257
136,914 135,135
8,486 70
83 2,608
191,642 154,070
6,557 6,733
– 57,135
198,199 217,938
┃ 167
6.
35,353 10,438
21,533 17,752
16 4,585 4,292
5,683 3,080
580,975 682,156
28 (3,396) 51,014
6,557 6,733
290,559 (57,135)
378,284 232,263
66,460 38,974
6,411 6,354
129,477 126,444
580,632 404,035
7.
14(b) 2,704 2,560
8,063 82
6,278 –
17,045 2,642
168 ┃
8.
383(1)(a) (b) (c) (f) 2
720 753
6,409 4,475
3,888 2,304
96 90
16,142 26,314
27,255 33,936
33
(a)
– –
360 360
360 360
720 720
┃ 169
8.
(a)
– –
– –
– 6
– 6
– 5
– –
– –
– 5
170 ┃
8.
(b)
– 4,247 3,240 – 16,142 ** 23,629
– 2,162 648 96 – 2,906
– 6,409 3,888 96 16,142 26,535
– – – – – –
* – – – – – –
– – – – – –
– – – – – –
* – – – – – –
– – – – – –
– 6,409 3,888 96 16,142 26,535
┃ 171
8.
(b)
33 3,143 1,680 – 24,557 ** 29,413
– 1,326 624 90 1,752 3,792
33 4,469 2,304 90 26,309 33,205
– – – – – –
– – – – – –
– – – – – –
* – – – – – –
* – – – – – –
– – – – –
33 4,469 2,304 90 26,309 33,205
*
**
172 ┃
9.
8
11,861 9,730
4,184 3,261
343 253
54,105 48,113
70,493 61,357
4,500,001 5,000,000 1 –
9,000,001 9,500,000 – 1
10,500,001 11,000,000 – 1
15,500,001 16,000,000 1 –
17,000,001 17,500,000 – 1
28,000,001 28,500,000 1 –
30,500,001 31,000,000 1 –
36,500,001 37,000,000 – 1
4 4
33
┃ 173
10.
16.5% 16.5%
2,000,000
2,000,000 8.25% 8.25%
16.5% 16. 5%
25%
15%
15%
15% 25%
50,000,000 25%
26% 50,000,000 30%
30%
174 ┃
10.
21% 21%
– 52,593
– (6,035)
– 46,558
(893,727) (20,121)
25% (223,432) (5,030)
97,152 22,370
65,183 (23,565)
(62,491) (56,802)
– (82,003)
103,983 134,184
18,148 4,720
1,457 91
– 52,593
– 46,558
1,511,700,000
┃ 175
11.
12.
(886,593) (64,545)
1,479,565 1,366,261
176 ┃
13.
81,041 119,569 7,996 6,675 230,724 446,005
– (11,917) (3,037) (970) – (15,924)
81,041 107,652 4,959 5,705 230,724 430,081
81,041 107,652 4,959 5,705 230,724 430,081
– 43,717 1,630 1,908 229,509 276,764
(7,766) (23,281) (2,575) (2,918) – (36,540)
143,367 74,899 309 26,854 (262,583) (17,154)
– 8 4 – – 12
216,642 202,995 4,327 31,549 197,650 653,163
224,408 238,193 9,939 35,437 197,650 705,627
(7,766) (35,198) (5,612) (3,888) – (52,464)
216,642 202,995 4,327 31,549 197,650 653,163
┃ 177
13.
– 10,339 3,567 1,078 296,929 311,913
– (3,725) (1,736) (54) – (5,515)
– 6,614 1,831 1,024 296,929 306,398
– 6,614 1,831 1,024 296,929 306,398
– 7,900 2,329 5,597 118,280 134,106
– (21) – – – (21)
– (8,193) (1,301) (916) – (10,410)
81,041 101,345 2,099 – (184,485) –
– 7 1 – – 8
81,041 107,652 4,959 5,705 230,724 430,081
81,041 119,569 7,996 6,675 230,724 446,005
– (11,917) (3,037) (970) – (15,924)
81,041 107,652 4,959 5,705 230,724 430,081
(a)
5
(b)
3
178 ┃
14.
50
1 6
(a)
21,910 74,823 96,733
58,709 – 58,709
(17,876) (1,543) (19,419)
(24) – (24)
62,719 73,280 135,999
9,542 163,368 172,910
(20,065) (4,810) (24,875)
69 – 69
52,265 231,838 284,103
160,101,000
29
(a)
6,640 1,650
(b) 3,350
┃ 179
14.
(b)
67,778 23,998
9,542 58,694
2,704 2,560
(73) –
(24,478) (17,445)
78 (29)
55,551 67,778
20,112 20,336
35,439 47,442
40
(c)
2,704 2,560
24,875 19,419
1,943 810
(73) –
29,449 22,789
34(c)
180 ┃
15.
3,125 3,125
5
5
5
60.7%-90% 21.5%~90%
0% 0%
14.48% 14.1%
┃ 181
15.
16.
36,580 2,431 39,011
(3,658) (1,187) (4,845)
32,922 1,244 34,166
32,922 1,244 34,166
– 11,724 11,724
(3,658) (927) (4,585)
29,264 12,041 41,305
36,580 13,096 49,676
(7,316) (1,055) (8,371)
29,264 12,041 41,305
182 ┃
16.
36,580 1,280 37,860
– (843) (843)
36,580 437 37,017
36,580 437 37,017
– 1,441 1,441
(3,658) (634) (4,292)
32,922 1,244 34,166
36,580 2,431 39,011
(3,658) (1,187) (4,845)
32,922 1,244 34,166
17.
11,712 21,423
2,000,000 50% 50% 50%
2,000,000 50% 50% 50%
┃ 183
17.
9,711 604
9,711 604
11,712 21,423
18.
– 32,000
14,947 9,566
8,273 6,147
4,822 3,238
28,042 50,951
19.
25,753 794
– 1,853
16,013 –
23,556 7,271
65,322 9,918
184 ┃
20.
127,957 45,304
(132) (31)
127,825 45,273
127,822 45,273
3 –
127,825 45,273
31 –
100 32
1 –
– (1)
132 31
┃ 185
20.
127,957 0.10% 132
45,304 0.07% 31
21.
44,987 41,363
33,557 37,532
12,147 17,362
– 16,340
4,653 3,548
95,344 116,145
186 ┃
22.
39
313,290 317,059
– 304,675
313,290 621,734
23.
8,697,927 5,928,716
(4,515,379) (2,691,009)
(2,564) (223)
4,179,984 3,237,484
3,947,918 3,106,954
215,970 103,064
16,096 27,466
4,179,984 3,237,484
┃ 187
24.
111,186 84,459
7,335 121
66 17
10 5
118,597 84,602
90
25.
4,242 6,831
13,541,000
4,242,000 18,749,000
6,831,000
188 ┃
26.
104,050 46,956
57,014 41,406
32,580 37,360
7,628 33,070
51,391 23,024
459,517 –
– 20,000
15,372 3,070
727,552 204,886
27.
7,757 12,647
278,203 123,611
285,960 136,258
136,258 106,646
197,062 45,868
(46,051) (16,256)
(1,309) –
285,960 136,258
┃ 189
28.
– 1,200,564
1,197,168 –
1,149,550
51,014
1,200,564
(3,396)
1,197,168
930 6.5%
39
29.
37,693 –
250,627 37,693
(559) –
287,761 37,693
50,000,000
325,000,000 0.35%
14
190 ┃
30.
5,432 6,036
(604) (604)
4,828 5,432
5,432 –
(604) 5,432
4,828 5,432
– –
– –
┃ 191
31.
50,000 500,000,000
0.0001 25,000,000,000
0.000002
1,764,321,452 1,499,673,235
0.000002 23 19
1,168,170 16 6,743,236
a) 210,508 3 2,526,672
31,171 – 101,818
1,409,849 19 9,371,726
A b) 264,648 4 2,919,066
– – (149,902)
– – (453,239)
7,713 – 68,629
1,682,210 23 11,756,280
a) 18,895,000 184,815,000 6,798,000 14.45 VIVO
OPPORTUNITY FUND L.P. GAOLING FUND L.P. YHG INVESTMENT, L.P.
b) A 264,648,217 0.000002 11.03
2,919,070,000
192 ┃
32.
(a)
i. 10%
ii. King Bridge 6.59
(b)
33.
A 0.000002 A
B 0.000002 B
┃ 193
33.
10 183,888,050 B
10 22,200,000 B
10 68,498,464 B
10
10% 10%
194 ┃
33.
0.1261 37,571 0.0511 62,851
0.1780 2,700 0.1487 13,241
0.1133 (2,725) 0.0297 (7,350)
0.0825 (7,713) 0.0071 (31,171)
0.1433 29,833 0.1261 37,571
1.2028 1.7236
3,225 0.000002 1-10-20 2-9-31
2,475 0.055 16-3-22 15-9-31
24,133 0.178 2-8-20 15-9-32
29,833
7,989 0.000002 1-11-18 15-9-31
3,000 0.055 30-9-20 15-9-31
26,582 0.178 2-8-20 7-10-31
37,571
┃ 195
33.
(%) 42.68-46.57 43
(%) 2.19-3.42 1.33-1.63
10 10
1.2690-1.4015 2.3591-2.8699
126.4
129.5
52,278,537
2.96%
34.
(a)
9,542,000 9,542,000 58,694,000
58,694,000
49,217,000 4,965,000
196 ┃
34.
(b)
– 1,200,564 37,693 67,778 1,306,035
– – 324,441 (24,478) 299,963
453,239 (3,396) – – 449,843
– – (84,788) – (84,788)
– – – 78 78
– – – 9,542 9,542
– – – (73) (73)
6,278 – 10,415 2,704 19,397
459,517 1,197,168 287,761 55,551 1,999,997
1,149,550 – 23,998 1,173,548
– 50,000 (17,445) 32,555
51,014 – – 51,014
– (12,420) – (12,420)
– – (29) (29)
– – 58,694 58,694
– 113 2,560 2,673
1,200,564 37,693 67,778 1,306,035
┃ 197
34.
(c)
1,943 810
24,478 17,445
26,421 18,255
35.
325,000,000 14 29
36.
130,956 61,464
2015 5 5
BTK
BTK
BTK (1)
(2)
BTK
BTK
BTK
198 ┃
37.
(a)
23,306 19,455
252 320
59,397 62,527
82,955 82,302
(b)
Beijing Baiaozhihui Technology Co., Ltd.
Beijing Baiaozhihui
Dimi Biological Medicine Technology
(Shanghai) Co., Ltd. Dimai
Vivo Opportunity Fund, L.P. 5%
VivoOpportunity Co-Invest, L.P.
┃ 199
37.
(c)
(i) 507 642
(ii) – 33,159
Beijing Baiaozhihui – 73
Dimai – 6
507 33,880
(iii) 134 –
20,000 –
(i)
(ii)
(iii)
(iv)
(v)
(vi) Vivo Opportunity Fund, L.P. Vivo Opportunity Co-Invest, L.P. 14.45
18,895,000
200 ┃
37.
(d)
134 –
– 20,000
117 252
117 20,252
┃ 201
38.
127,825 – 127,825
– 313,290 313,290
49,640 – 49,640
8,697,927 – 8,697,927
8,875,392 313,290 9,188,682
118,597 – 118,597
287,761 – 287,761
637,959 – 637,959
– 1,197,168 1,197,168
1,044,317 1,197,168 2,241,485
202 ┃
38.
45,273 – 45,273
– 621,734 621,734
44,911 – 44,911
5,928,716 – 5,928,716
6,018,900 621,734 6,640,634
84,602 – 84,602
37,693 – 37,693
96,178 – 96,178
– 1,200,564 1,200,564
218,473 1,200,564 1,419,037
┃ 203
39.
– 313,290 – 313,290
– 621,734 – 621,734
204 ┃
39.
– – 1,197,168 1,197,168
– – 1,200,564 1,200,564
(i)
28
(%)
1,197,168 2.15~4.30
1,200,564 2.45~4.60
┃ 205
39.
(i)
1%
2.15%
(11,430)/11,652
1%
2.45%
(34,381)/35,746
1%
2.15%
(8,533)/8,698
1%
2.15%
(4,805)/4,992
206 ┃
40.
%
5 5,237
(5) (5,237)
5 191
(5) (191)
5 2,245
(5) (2,245)
5 923
(5) (923)
┃ 207
40.
12
1 2 3
– – – 127,825 127,825
49,640 – – – 49,640
8,697,927 – – – 8,697,927
8,747,567 – – 127,825 8,875,392
12
1 2 3
– – – 45,273 45,273
44,911 – – – 44,911
5,928,716 – – – 5,928,716
5,973,627 – – 45,273 6,018,900
208 ┃
40.
118,597 – – 118,597
654,778 – – 654,778
23,822 37,799 – 61,621
1,138 379,856 – 380,994
a 1,242,325 – – 1,242,325
2,040,660 417,655 – 2,458,315
84,602 – – 84,602
96,178 – – 96,178
22,687 50,646 – 73,333
– 50,875 – 50,875
a – 1,302,775 – 1,302,775
203,467 1,404,296 – 1,607,763
(a)
┃ 209
40.
287,761 37,693
1,197,168 1,200,564
459,517 –
1,944,446 1,238,257
10,321,158 7,397,531
19% 17%
210 ┃
41.
2,450,509 1,590,003
6,970,068 4,705,282
41,201 53,256
9,461,778 6,348,541
12,944 2,953
12,944 2,953
9,448,834 6,345,588
9,448,834 6,345,588
9,448,834 6,345,588
23 19
9,448,811 6,345,569
9,448,834 6,345,588
9,371,725 602 260,235 (515,562) (2,771,431) 6,345,569
– – – – (392,089) (392,089)
– – – 591,944 – 591,944
– – – 591,944 (392,089) 199,855
A 2,919,066 – – – – 2,919,066
(149,440) – – – – (149,440)
– – 129,477 – – 129,477
68,629 – (64,345) – – 4,284
12,209,980 602 325,367 76,382 (3,163,520) 9,448,811
┃ 211
41.
6,743,235 602 234,183 (405,261) (2,769,771) 3,802,988
– – – – (1,660) (1,660)
– – – (110,301) – (110,301)
– – – (110,301) (1,660) (111,961)
2,526,672 – – – – 2,526,672
– – 126,444 – – 126,444
101,818 – (100,392) – – 1,426
9,371,725 602 260,235 (515,562) (2,771,431) 6,345,569
42.
MS
BTK
90
43.
212 ┃
2022 ESG
214
1.
1.1 216
1.2 ESG 219
1.3 221
2. 6.
2.1 223 6.1 254
2.2 224 6.2 256
2.3 226 7.
3. 7.1 258
3.1 229 7.2 259
3.2 233 7.3 260
3.3 237 8. 261
4 9.
4.1 239
4.2 241 267
4.3 243
1 (2022)
5.
269
5.1 248
5.2 248
2 272
5.3 250
5.4 252
09969.HK 688428.SH
2022 1 1 2022 12 31
2022 1
1
2
214 ┃
ESG
(www.innocarepharma.com)
(www.hkexnews.hk) http://www.sse.com.cn/
Email ir@innocarepharma.com
┃ 215
1.
1.1
2015
9969.HK
688428.SH
216 ┃
1.
2022
CD20xCD3 ICP-B02
II
II
TYK2 JH2 ICP-488
RTK ICP-033
2022 (AACR) ICP-723
2021
ICP-490
2022
Tafasitamab (NMPA) II
┃ 217
1.
2022 (EULAR)
2022 (ASCO)
Tafasitamab DLBCL (CSCO)
PD-1 PCNSL 2022 (EHA)
16
CCR8 ICP-B05
SHP2 ICP-189
ICP-490 (MM)
(NHL)
BCL2 ICP-248
Tafasitamab DLBCL
TYK2 JH2 ICP-488
CCR8 ICP-B05
Tafasitamab DLBCL
RCHOP non-GCB DLBCL 2022
(ESMO)
(NMPA) (CDE) BTK
(MZL)
Tafasitamab DLBCL II
BCL2 ICP-248
H+A
218 ┃
1.
Tafasitamab
eClinicalMedicine II
2022
TRK ICP-723
Tafasitamab B
10 64 (ASH)
(HSA) (R/R
MCL)
2022 21
Tafasitamab B
2022
2022
IPO
2021
2022 TOP100
1.2 ESG
ESG ESG ESG
ESG ESG
ESG ESG
┃ 219
1.
ESG
ESG
ESG
ESG
ESG ESG ESG
ESG
ESG
ESG
ESG
ESG
ESG
ESG ESG
2022 ESG ESG
ESG ESG ESG
ESG
ESG 2022 12
2022
220 ┃
1.
1.3
ESG
ESG
ESG ESG
┃ 221
1.
ESG
ESG
ESG 16
222 ┃
2.
2.1
2022
2022 10
2022
9 1
13
3
8
3 68
┃ 223
2.
2.2
2
H A
2022 6 21
224 ┃
2.
(www.hkexnews.hk)
(www.innocarepharma.com)
2022
900
A
2022 H+A
IPO
IR
┃ 225
2.
2.3
EHS
226 ┃
2.
EHS EHS
EHS
EHS
10
┃ 227
2.
MRP 43
EHS
2022
228 ┃
3.
3.1
2015
CMC
2022 NMPA
BTK
┃ 229
3.
CMC
CRO
430 43.8%
2022
first-in-class CM369
CCR8 CM369
Tafasitamab 13 30
230 ┃
3.
2022
IND Enabling Filed Market
PHIa PHIb PH2* PH2** PH3
ICP-022/
BTK
Orelabrutinib
ICP-332 TYK2 – JH1
ICP-488 TYK2 – JH2
ICP-192/ pan-FGFR
Gunagratinib
ICP-723/
pan-TRK
Zurletrectinib
ICP-033 VEGFR, DDR1
ICP-189 SHP2
ICP-B05 CCR8
NDA
IND Enabling Filed Market
PHIa PHIb PH2* PH2** PH3
CHN
r/r CLL/SLL
CHN,SG
r/r MCL
r/r MZL
r/r WM
BTK 1L: CLL/SLL
ICP-022/
Orelabrutinib
1L: MCL
1L: MCD DLBCL
r/r MCL
HK
Tafa + LEN, r/r DLBCL
ICP-B04/
CD19
Tafasitamab
Tafa + LEN + Orela
NHL
ICP-B02 CD3 x CD20
ICP-248 BCL-2 NHL/ALL/
MM / DLBCL /
ICP-490 E3 Ligase
ICP-B05 CCR8 Hemato-oncology
NDA
┃ 231
3.
2022
2022
2022
2021
(GCP)
SOP
(GB/T 35892-2018)
(IACUC)
232 ┃
3.
2022
48
275 54
3.2
(GMP) (GCP) (GLP)
(ICH)
┃ 233
3.
(FMEA)
(HACCP)
GMP
CAPA
2022
(Qualified Person) MAH
GLP
(ICH-GCP)
234 ┃
3.
QA
MAH
CAPA
┃ 235
3.
50mg
(400-635-1999)
(PV@innocarepharma.com)
(PV)
236 ┃
3.
3.3
2022 11
IDC
┃ 237
3.
(info@innocarepharma.com) (400-635-1999)
2022 8 100%
238 ┃
4.
4.1
┃ 239
4.
2022
10 12 15
2 20 25
2022
240 ┃
4.
HR
4.2
┃ 241
4.
100% 2022 11
200
80
Excel
Orientation
CEO
2023 3 2018 8
1,110,000 7 610,000
242 ┃
4.
4.3
EHS Environment, Health and
Safety
EHS EHS
EHS EHS
EHS 565 EHS ISO 45001
EHS EHS EHS CEO
EHS 2022
EHS
EHS
┃ 243
4.
EHS
11 2022 EHS
0 0 2022 EHS
QC QC
2022 37 260
2022 EHS
244 ┃
4.
2022 382
2022 29
2022 26
2022 6
EHS 2022
1,083
2022
100%
┃ 245
4.
2022
EHS&MARATHON
2022 6 21
5 100%
246 ┃
4.
2022 5
2022 2,707,806
┃ 247
5.
5.1
ISO 14001
2022
2022
2021
ESG
5.2
248 ┃
5.
26 20
EHS
┃ 249
5.
5.3
2016
(COD) (BOD)
250 ┃
5.
┃ 251
5.
5.4
(Task Force on
Climate-related Financial Disclosures, TCFD)
ESG
252 ┃
5.
┃ 253
6.
6.1
ISO 37301
2022
(www.innocarepharam.com)
254 ┃
6.
2022 17
832
2022
2022
(www.innocarepharam.com)
legal_compliance@innocarepharma.com
8 102206
┃ 255
6.
6.2
256 ┃
6.
EHS
EHS
┃ 257
7.
7.1
2022
2022 (AACR) TRK ICP-723
(BTK)
2022 (EULAR)
FGFR 1-4 gunagratinib (ICP-192)
FGF/FGFR I
2022 (ASCO) TRK ICP-723
(PK)
B
PD-1
2022 (EHA)
(PCNSL) II
258 ┃
7.
RCHOP non-GCB
2022 (ESMO)
B (DLBCL) 2022 ESMO
(BTK) 10 ASH
(HD-MTX)
(PCNSL)
III
64 (ASH)
R-CHOP R-CHOP MCD
B
PD-1
I/II
RCHOP B
7.2
2022
11 (HSA) (R/
R MCL) 2022 7 tafasitamab Minjuvi
DLBCL Tafasitamab
18 B
tafasitamab
2021
28
tafasitamab
┃ 259
7.
2022 Tafasitamab
2022 (CSCO)
(ASCT) B (DLBCL) II
CSCO
7.3
2022
2022 3 1
50
23.7
2022
CEO
2021
16
2022
260 ┃
8.
2022
62,540.4
(0.63)
0.25
1 = + + +
2020 2021 2022
1,991.10 8,667.30 10,820.95
2,895.16 9,894.90 9,380.31
6.41 13.72 9.56
56,311.00 145,093.00 124,940.00
124.58 201.24 127.36
0.00 0.75 1.8
0.001 0.002
82,843 99,527
(COD) 2,469 1,396
(BOD) 417 381
(NH3-N) 82 29
37,180,000
(VOC) 23.62
270.86
49.06
14.3
1,926.00 2,874.54 1,074.10
30.10 106.79 115.05
4.26 3.99 1.09
0.07 0.15 0.12
┃ 261
8.
2020 2021 2022
1
CO2 2,476.59 9,236.40 9,835.80
2
CO2 0 0 0
3
CO2 2,476.59 9,236.40 9,835.80
CO2 5.48 12.81 10.03
0 0 0
1
2021 5
2 0
3 2023 2025
2021 0.6101 0.5703
2019 2008 2020 0.11
0.1286 2020 2021
2020 2021 2022
1
452 721 981
234 350 457
218 371 524
448 698 939
4 13 21
0 10 21
30 176 230 332
30-50 260 472 628
50 16 19 21
444 707 967
8 14 14
581 806
134 169
6 6
262 ┃
8.
2020 2021 2022
1
% 15.26 13.76
% 11.00 14.57 15.32
% 7.00 15.90 12.40
30 % 15.00 16.52 18.98
30-50 % 13.00 14.41 11.31
50 2
% 0.00 21.05 4.76
% 9.00 15.28 13.75
% 0.00 14.29 14.29
0 0 0
% 0 0 0
0 0 0
3
% 100.00 100.00 100.00
% 100.00 100.00 100.00
% 100.00 100.00 100.00
% 100.00 100.00 100.00
% 100.00 100.00 100.00
% 100.00 100.00 100.00
4
10.00 25.00 28.20
10.00 30.00 28.43
8.00 21.00 28.01
8.00 19.00 22.30
12.00 53.00 56.26
18.00 30.00 30.83
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
┃ 263
8.
1 = *100%
2 2021 50 2021/2022 50
3 = *100%
4 =
2020 2021 2022
500 587 722
488 575 687
1
12 12 35
0 0 0
0 0 0
0 0 0
0 0 0
1
264 ┃
8.
2020 2021 2022
0 0 0
0 0 0
0 0 0
0 0 0
0 0 0
0 0 8
% 0.00 0.00 0.00
2020 2021 2022
100.00 100.00 76.80
18.40
50.00
8.40
┃ 265
8.
2020 2021 2022
0 0 0
1
172 648 920
1
0.19 0.45 0.61
1
% 0 22.22 33.33
1
0 0.22 0.67
1 2022
2020 2021 2022
402,711 721,584 64,489
% 295 69 99
193 286 418
% 48.2 46.9 46.4
% 37.8 36.4 38.5
% 12.4 14.3 12.2
48
17 18
42
63
225 275
37 54
266 ┃
9.
A. A3. 5.1
A1. 5.3 5.1 5.2
5.1 5.3 A3.1 5.3
A1.1
A1.2 A4. 5.4
A1.3 A4.1 5.4
A1.4 B.
5.1 5.3
A1.5
B1. 4.1
5.1 5.3 B1.1
A1.6
B1.2
A2. 5.2
B2. 4.3
A2.1
B2.1
A2.2
B2.2
5.1 5.2
A2.3 B2.3 4.3
5.1 5.2
A2.4
A2.5
┃ 267
9.
B3. 4.2 B6.3 3.1
B3.1 B6.4 3.2
B3.2 B6.5 3.3
B4. 4.1 B7. 6.1
B4.1 4.1 6.1
B7.1
B4.2
B7.2 6.1
B5. 6.2 6.1
B7.3
B5.1
B5.2 6.2
7.2 7.3
B5.3 6.2 B8.
B5.4 6.2
7.2 7.3
B6. 3.2 B8.1
B6.1 B8.2
B6.2 3.3
268 ┃
9.
1 (2022)
1.2 ESG 2.1 2.2
3.2 3.3 4.1
8.1
5.1 6.2 7.3
8.2 1.2 ESG 3.1 6.1
8.3 1.2 ESG
8.4
8.5
1.2 ESG 3.2
8.6
4.1 5.1 7.2
8.6
7.3
8.6
8.7 2.1 4.1
8.8 5.1
8.8 5.1
8.8 5.2
8.8 5.3
8.8 5.3
8.8 5.1
8.8 6.2
8.8 5.1
┃ 269
9.
8.9 5.1
8.9
8.9 5.1
8.9 5.1 5.3
8.9 5.1
8.9 5.3
8.9
8.9
5.1 5.2 5.3
8.9
5.4
8.10
8.10
8.10
8.10
8.10
8.10
270 ┃
9.
8.11 5.1
5.3
8.12
2022
5.1 5.2 5.3
8.12
8.12 5.1
8.12 5.3
8.13 3.2
8.13 3.2
8.13 3.2
8.13 6.2
8.14 4.1
8.14 4.3
8.14 4.2
4.1 4.2 4.3
8.14
8.15 3.1
┃ 271
9.
2
-1 3.1
-2 3.1
-3 3.1
-4 3.1
5.1 5.2 5.3
-1
4.1 4.2 4.3
-2
3.2 3.3 6.1
-3
7.2 7.3
2.1 2.2 2.3
-4
272 ┃
SCIENCE DRIVES
INNOVATION
FOR THE BENEFIT OF PATIENTS
科學驅動創新
患者所需為本